



# S1316- MBO STUDY

July 7th, 2016

In this issue:

- Accrual Update
- Open Sites
- Tracking Log
- Reminders
- Octreotide Shortage
- Coordinators Call
- Study Information



**Welcome** to the MBO Study monthly newsletter. Our research team has created this newsletter to provide you with the latest news about this study. If you would like to contribute to the newsletter send your comments or questions to Octavio Bojorquez at [obojoqrqu@email.arizona.edu](mailto:obojoqrqu@email.arizona.edu).

## Study Accrual through June 30th, 2016

Accrual by Site				
Site Name	N Randomized	N Patient Choice	N Total	% Total
TOTAL ACCRUAL	1	32	33	100
City of Hope Comprehensive Cancer Center	0	1	1	3
Columbia University/Herbert Irving Cancer Center	0	1	1	3
Duke University Medical Center	0	6	6	18
Long Island Jewish Medical Center	0	2	2	6
Medical University of South Carolina	0	5	5	15
North Shore University Hospital	0	1	1	3
Rhode Island Hospital	0	1	1	3
The University of Arizona Medical Center-University Campus	0	5	5	15
University of Arkansas for Medical Sciences	0	4	4	12
University of Michigan Comprehensive Cancer Center	1	4	5	15
University of Oklahoma Health Sciences Center	0	2	2	6

## Open Sites

University of Arizona	City of Hope	Baylor UMC Dallas	Duke University	Columbia University
Medical University of South Carolina	University of Oklahoma	University of Michigan	Essentia Health C C Minnesota	University of Arkansas
Rush University Medical Center	Medical College of Wisconsin	University of Massachusetts	Rhode Island (Brown)	University of Kansas
Northwell Health				MD Anderson

## Tracking Log

**S1316 Patient Accrual Tracking Log** to keep track of all potential patients. Please send the log to our team *once a month*. The log is available at the SWOG study webpage or you can request one from Octavio Bojorquez.

Investigator									
Participant Site									
Row	Month	Patient initials <i>(redact for submission to S1316 team)</i>	Confirmed MBO patient? (Y/N)	When was patient admitted? <i>(regular hours, after hours, weekend, holiday)</i>	Was patient ever considered for study participation? (if not, list reason why not considered)	Was the patient ever approached for study participation? (If not, list reason why not approached)	Was the patient eligible for study participation? (If not, list the reason why not eligible)	Was the patient willing to participate (if not, list reason why not willing)	Was the patient registered? (if not, list reason why not registered)

- If you need more protocol cards, or have not received them, contact Octavio Bojorquez at (520) 286-1273 or [obojoqrqu@email.arizona.edu](mailto:obojoqrqu@email.arizona.edu). Please make sure to **update** them so they will reflect the expanded **two week** window for pre-registration scans. You can use a permanent marker to cover the previous requirement and to add the new **two weeks**.
- Upload discharge summaries **in Rave** within 14 days of discharge.



## Octreotide Shortage

It has come to our attention that there is a national shortage of Octreotide, the agent on formulary for the S1316 MBO study. Per S1316 protocol, it is appropriate to use the depot form or any other metastat analog; see Section 7.3 for a complete list. It does not have to be Octreotide.

## Coordinators Call

We have a monthly (30-60 minute) teleconference for coordinators from open and planning-to-open study sites to discuss study issues with the research team. Our next call will be Wednesday July 13<sup>th</sup>, 1:00 P.M. ET, 12:00 P.M. CT, and 10:00 A.M. PT. The number to call is 1-855-295-4424. Conference code is 6221480#.



## STUDY INFORMATION

Study information is available at <http://swog.org> and CTSU at <https://www.ctsu.org>. Have suggestions for our newsletter? Send your comments or suggestions to Octavio at [obojoqrqu@email.arizona.edu](mailto:obojoqrqu@email.arizona.edu).

Have a question for the PI Dr. Robert S. Krouse? Feel free to call his cell phone at (520) 631-5642.

Or you can call Virginia Sun PhD., RN cell phone at (626) 257-4717.

Please use [cancercontrolquestion@crab.org](mailto:cancercontrolquestion@crab.org) for S1316 questions related to study forms or data submission.